Key facts
- Minovia Therapeutics’s last known valuation is $86.3M (Dec 2018).
- It has raised $16.1M; the latest was PIPE ($18.0M) in Jun 2025.
- Notable investors include Vincent Tchenguiz, Countdown for a Cure Foundation, EIT Health, Gold Track, Yozma.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Minovia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Minovia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Minovia Therapeutics
Developer of mitochondrial augmentation therapy designed to treat mitochondrial diseases. The company's platform repairs damaged mitochondrial DNA by using autologous stem cells enriched with blood-derived mitochondria that enrich patients' hematopoietic stem cells with healthy donor mitochondria, compatible assays, and scalable manufacturing, enabling medical practitioners to extend and enhance human lives and to receive personalized treatment that enhances mitochondrial function and supports healthier life outcomes.
- Sector
- Healthcare
- HQ
- Tirat Hacarmel, Israel
- Founded
- 2011
- Employees
- 28
- Website
- minoviatx.com/
- Ownership
- Privately Held (backing)
Minovia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Minovia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Minovia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.